Bruno Halpern

2.7k total citations · 2 hit papers
51 papers, 835 citations indexed

About

Bruno Halpern is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology and Pharmacology. According to data from OpenAlex, Bruno Halpern has authored 51 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 20 papers in Physiology and 14 papers in Pharmacology. Recurrent topics in Bruno Halpern's work include Diet and metabolism studies (16 papers), Pharmacology and Obesity Treatment (14 papers) and Diabetes Treatment and Management (14 papers). Bruno Halpern is often cited by papers focused on Diet and metabolism studies (16 papers), Pharmacology and Obesity Treatment (14 papers) and Diabetes Treatment and Management (14 papers). Bruno Halpern collaborates with scholars based in Brazil, United States and United Kingdom. Bruno Halpern's co-authors include Márcio C. Mancini, Alfredo Halpern, Shuyu Zhang, Nadia N. Ahmad, Sriram Machineni, Mathijs C. Bunck, Robert F. Kushner, Tammy Forrester, Jamy D. Ard and Ariana M. Chao and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Bruno Halpern

44 papers receiving 808 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

2023 220 citations Thomas A. Wadden, Ariana M. Chao et al. Nature Medicine profile →
Tirzepatide for Obesity Treatment and Diabetes Prevention

2024 133 citations Ania M. Jastreboff, Carel W. le Roux et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruno Halpern Brazil	14	367	310	283	138	131	51	835
Christian R. Juhl Denmark	12	353 1.0×	278 0.9×	258 0.9×	123 0.9×	144 1.1×	26	816
Naji Alamuddin United States	20	259 0.7×	262 0.8×	241 0.9×	250 1.8×	119 0.9×	45	1.1k
Altynai Satylganova Denmark	9	471 1.3×	246 0.8×	342 1.2×	153 1.1×	199 1.5×	12	780
Katrine Bagge Hansen Denmark	20	608 1.7×	370 1.2×	147 0.5×	413 3.0×	321 2.5×	52	1.2k
Nader Lessan United Kingdom	13	365 1.0×	607 2.0×	89 0.3×	177 1.3×	59 0.5×	41	959
Jack A. Sargeant United Kingdom	18	406 1.1×	465 1.5×	107 0.4×	127 0.9×	224 1.7×	54	1.0k
Arash Pakseresht Denmark	7	707 1.9×	257 0.8×	499 1.8×	233 1.7×	310 2.4×	12	975
George Valsamakis Greece	15	284 0.8×	286 0.9×	134 0.5×	80 0.6×	116 0.9×	25	974
Stanley H. Hsia United States	14	494 1.3×	118 0.4×	129 0.5×	145 1.1×	179 1.4×	25	793
Rebecca Christensen Canada	12	170 0.5×	159 0.5×	224 0.8×	173 1.3×	100 0.8×	44	603

Countries citing papers authored by Bruno Halpern

Since Specialization

Citations

This map shows the geographic impact of Bruno Halpern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Halpern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Halpern more than expected).

Fields of papers citing papers by Bruno Halpern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Halpern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Halpern. The network helps show where Bruno Halpern may publish in the future.

Co-authorship network of co-authors of Bruno Halpern

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Halpern. A scholar is included among the top collaborators of Bruno Halpern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Halpern. Bruno Halpern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hegazi, Refaat & Bruno Halpern. (2025). Looking beyond fat in obesity: the frequently overlooked importance of muscle mass. Reviews in Endocrine and Metabolic Disorders. 26(5). 719–721.

Valério, Cynthia Melissa, José Francisco Kerr Saraiva, Simone van de Sande‐Lee, et al.. (2025). 2025 Brazilian evidence-based guideline on the management of obesity and prevention of cardiovascular disease and obesity-associated complications: a position statement by five medical societies. Diabetology & Metabolic Syndrome. 17(1). 432–432.

Correia, María Isabel Toulson Davisson, Nitin Kapoor, Luís Henrique Wolff Gowdak, et al.. (2025). Emerging evidence and potential avenues to achieve durable outcomes in patients with obesity: the confluence of nutrition, and Microbiome on body composition. Reviews in Endocrine and Metabolic Disorders. 26(5). 745–758.

Wharton, Sean, Louis J. Aronne, Adam Stefański, et al.. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 393(18). 1796–1806. 10 indexed citations

Janovsky, Carolina Castro Porto Silva, et al.. (2025). Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis. International Journal of Obesity. 49(12). 2415–2425.

Generoso, Giuliano, Bruno Halpern, Carolina Castro Porto Silva Janovsky, et al.. (2025). Waist-to-height ratio and coronary artery calcium incidence: the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). The Lancet Regional Health - Americas. 52. 101281–101281.

Mandel, Francine S., et al.. (2025). Exploring the perceptions of obesity, health habits, stigma, and eating behaviors in Brazil. Diabetology & Metabolic Syndrome. 17(1). 119–119.

Artime, Esther, Caragh Flannery, Victoria Higgins, et al.. (2025). Experiences and overall impact reported by people living with obesity: results from a multinational study. SAGE Open Medicine. 13. 3932163898–3932163898. 1 indexed citations

Wadden, Thomas A., Ariana M. Chao, Sriram Machineni, et al.. (2024). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Diabetologie und Stoffwechsel. 19(S 01). S83–S84. 1 indexed citations

10.

Jastreboff, Ania M., Carel W. le Roux, Adam Stefański, et al.. (2024). Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 392(10). 958–971. 133 indexed citations breakdown →

11.

Moreira, Rodrigo O., Cynthia Melissa Valério, Cristiane Alves Villela‐Nogueira, et al.. (2023). Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso). Archives of Endocrinology and Metabolism. 67(6). e230123–e230123. 11 indexed citations

12.

Wadden, Thomas A., Ariana M. Chao, Sriram Machineni, et al.. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. 29(11). 2909–2918. 220 indexed citations breakdown →

13.

Halpern, Bruno, Márcio C. Mancini, Simone van de Sande‐Lee, & Paulo Augusto Carvalho Miranda. (2023). “Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Archives of Endocrinology and Metabolism. 67(4). e230174–e230174. 6 indexed citations

14.

Halpern, Bruno, et al.. (2022). Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations. Diabetology & Metabolic Syndrome. 14(1). 37–37. 4 indexed citations

15.

Halpern, Bruno, et al.. (2020). Extrinsic compression of pancreactic duct by intragastric balloon treatment and its potential to cause acute pancreatitis: two case reports and clinical discussion. Obesity Research & Clinical Practice. 14(2). 191–193. 4 indexed citations

16.

Halpern, Bruno, Márcio C. Mancini, Camila Maria Longo Machado, et al.. (2020). Melatonin deficiency decreases brown adipose tissue acute thermogenic capacity of in rats measured by 18F-FDG PET. Diabetology & Metabolic Syndrome. 12(1). 82–82. 9 indexed citations

17.

Halpern, Bruno, et al.. (2020). Extrinsic compression of pancreatic duct by intragastric balloon treatment and its potential to cause acute pancreatitis: Two case reports and clinical discussion. Obesity Research & Clinical Practice. 14(3). 290–292. 3 indexed citations

18.

Campos, Luciana Aparecida, Clarissa Bueno, Isabella Peixoto de Barcelos, et al.. (2020). Melatonin Therapy Improves Cardiac Autonomic Modulation in Pinealectomized Patients. Frontiers in Endocrinology. 11. 239–239. 13 indexed citations

19.

Reis, André F., Letícia Schwerz Weinert, Sandra Pinho Silveiro, et al.. (2019). Targeted sequencing identifies novel variants in common and rare MODY genes. Molecular Genetics & Genomic Medicine. 7(12). e962–e962. 23 indexed citations

20.

Halpern, Bruno & Alfredo Halpern. (2015). Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opinion on Drug Safety. 14(2). 305–315. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact